Inmune Bio Inc Stock Price, News & Analysis

INmune Bio Inc. (NASDAQ: INMB) presented important findings at The 16th European Meeting on Glial Cells in Health and Disease in Berlin, Germany. The data shows that XPro™, by neutralizing soluble TNF, promotes remyelination in the cuprizone model by increasing astrocyte and microglia activation responses.

Key findings include:

• Astrocytes are rapidly activated in response to demyelination
• Preventing soluble TNF and TNFR1 function in mice mirrors XPro™'s effects
• Traditional biomarkers of astroglial and microglial activation (GFAP and Iba1) are increased in myelin-promoting glial cells

These results challenge the current belief that decreased glial activation is required for remyelination, suggesting that immunosuppressive therapies may not aid brain repair in neurologic diseases.

INmune Bio Inc. (NASDAQ: INMB) announces that its Chief Scientific Officer, Mark Lowdell, Ph.D., will deliver the opening plenary lecture at the International Society of Cell and Gene Therapy (ISCT) in Paris on May 31st. The talk, titled 'The Future of Immune Effector Cell Therapies for Cancer, Tumor-Primed Memory NK Cells – from Heresy to Clinical Trials,' will focus on INKmune™, the company's proprietary Natural Killer (NK) cell platform.

Dr. Lowdell's team has discovered that INKmune™ primes NK cells to a unique cancer-killing population of memory-like NK cells, differing from cytokine-primed NK cells. This breakthrough could potentially avoid complications associated with cytokine therapy. The company recently received FDA acceptance of its Investigational New Drug Application (IND) for treating metastatic castrate-resistant prostate cancer, with a Phase I/II study set to begin enrolling patients in the US later this year.